We explain mechanisms in plain language — what research observes, where the evidence is early, and what we will never claim.
It’s an ecosystem of trillions of microbes with different roles. “Good bacteria” is too simple — balance and diversity are what matter, and they shift with diet, stress, sleep and medication.
Akkermansia muciniphila lives in the mucin layer that lines the gut. It’s described as a major mucin-degrading bacterium — and because strains differ functionally, the specific strain (like AH39) matters.
A healthy gut barrier is linked in research to inflammation balance and metabolic signalling. Supporting the barrier environment is a central idea behind the metabolic formulas.
Akkermansia’s surface protein P9 has been linked to GLP-1 secretion via ileal L-cells — part of how the gut helps regulate glucose and lipid metabolism. We describe this as a research mechanism, not a drug effect.
The gut and brain talk constantly. Specific “psychobiotic” strains are studied for stress-response, mood and sleep-rhythm support — the basis of Mentabiotic and Neurobiome Reset.
Skin clarity and barrier health are connected to gut and inflammation balance. Skinbiotic is built around barrier-support strains for glow from within.
A randomized, double-blind, placebo-controlled exploratory study in overweight and obese insulin-resistant volunteers tested oral A. muciniphila for three months — reported as safe and well tolerated. Pasteurized A. muciniphila showed improvements in insulin sensitivity, insulinemia and total cholesterol versus placebo, with modest changes in body weight and fat mass.
| Design | Randomized, double-blind, placebo-controlled pilot |
| Participants | 40 enrolled · 32 completed |
| Duration | 3 months · 1010 bacteria/day |
| Outcome | Safe, well tolerated; favourable metabolic trends (pasteurized form) |
Described for education. Not a promise of results. Not a treatment for any disease.
Every strain we use, with its category, formulas, research area and a compliance-safe claim.
